ASH 2020 | Bortezomib-based triplet regimens in MM patients undergoing transplantation
Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the findings of a large CIBMTR registry study, comparing VRD (bortezomib, lenalidomide and dexamethasone) to VCD (bortezomib, cyclophosphamide and dexamethasone) induction therapy in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). 1135 transplant patients were identified who had shown at least a partial response to VCD or VRD induction therapy. Pre-transplant responses were comparable between groups, and no difference in outcome was seen based on induction therapy received once prognostic factors were adjusted for. The study also showed that maintenance treatment was associated with superior outcomes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
